Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage biopharmaceutical company focused on developing long-acting injectables (LAIs), today announced the positive results from its phase 1 ...

Alar Pharmaceuticals’ long-acting ketamine shows early potential in TRD

Alar’s ketamine-based drug mitigates certain adverse events, which could eliminate the need for post-dose monitoring.
Medscape

Urologists Reckon With Ketamine’s Toll on the Bladder

For patients with ketamine cystitis, the best treatment ‘isn’t a scalpel; it’s abstinence,’ according to a presentation at the European Association of Urology annual meeting.
The Victoria Advocate

Alar Pharmaceuticals Announces First Patient Dosing in a Study of ALA-3000 (Extended-Release Ketamine Injection) for Treatment-Resistant Depression (TRD)

TAICHUNG, May 14, 2025 /PRNewswire/ -- Alar Pharmaceuticals Inc. (Alar, TPEx:6785), a clinical-stage pharmaceutical company dedicated to the development of long-acting injectables to treat CNS ...
Psychology Today

Lumina Ketamine Therapy

I offer intramuscular (IM) ketamine injections for clients suffering from PTSD and treatment-resistant depression. I prefer to work in conjunction with your mental health professional, in-person or ...